Physician profile
Frederick A Corder
NPI 1710961982
$8,881.05
in general payments reported to CMS, 2019-2025
29 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $518 · 2021: $1,374 · 2022: $1,147 · 2023: $1,421 · 2024: $1,912 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,249.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,944.92 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,133.50 | 2020-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $754.82 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $507.31 | 2023-2025 | |
| Janssen Biotech, INC. | $453.65 | 2021-2025 | Stelara, Tremfya, Remicade |
| Qol Medical, LLC | $436.91 | 2021-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $339.33 | 2024-2025 | Vowst, Zenpep |
| Merck Sharp & Dohme LLC | $279.34 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $267.70 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $196.76 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $189.29 | 2021-2023 | |
| Daiichi Sankyo INC. | $188.64 | 2021-2022 | |
| Ardelyx, INC. | $133.61 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $120.85 | 2020-2021 | |
| Boston Scientific Corporation | $115.83 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $111.35 | 2023 | Stelara |
| Celgene Corporation | $105.71 | 2021-2024 | Zeposia |
| Fujifilm Healthcare Americas Corporation | $100.00 | 2025 | |
| Celltrion USA INC. | $99.26 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $75.43 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $72.88 | 2019-2023 | Linzess |
| Evoke Pharma, INC. | $64.74 | 2023-2025 | Gimoti |
| Lilly USA, LLC | $37.35 | 2024-2025 | Omvoh, Zepbound |
| Allergan, INC. | $36.42 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $35.23 | 2022-2023 | Ocaliva |
| Micro-Tech Endoscopy USA, INC. | $29.38 | 2024 | Snares |
| Mauna Kea Technologies, INC. | $21.67 | 2023-2024 | |
| Capsovision, INC. | $14.89 | 2025 | Capsocam Plus |
| Astrazeneca Pharmaceuticals LP | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Corder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.